DEVELOPING A NOVEL APPROACH TO ALLERGEN IMMUNOTHERAPY
OUR MISSION IS TO PROVIDE LONG-LASTING PEACE OF MIND TO FOOD ALLERGY SUFFERERS
Prota Therapeutics is an Australian biotech company developing a novel combination probiotic allergen oral immunotherapy platform for the treatment of food allergies. Our patented technology is based on two decades of research led by Professor Mimi Tang at the Murdoch Children’s Research Institute (MCRI), Melbourne, Australia. Our lead product, a combination probiotic peanut oral immunotherapy (PRT100), targets one of the most serious and potentially life-threatening allergies – peanut allergy. The combination probiotic food allergen oral immunotherapy technology is expected to offer a platform approach for treatment of other food allergies.
Prota’s food allergy treatments are investigational and are not approved for marketing in any region.